Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,533
archived clinical trials in
Kidney Cancer

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
Central Plains Clinic, Ltd.
mi
from
Sioux Falls, SD
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
Central Plains Clinic, Ltd.
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
Saskatchewan Cancer Agency
mi
from
Regina,
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
Saskatchewan Cancer Agency
mi
from
Regina,
Click here to add this to my saved trials
A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
Status: Enrolling
Updated:  11/22/2016
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
Status: Enrolling
Updated: 11/22/2016
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
City of Hope South Pasadena
mi
from
South Pasadena, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
mi
from
Hershey, PA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
mi
from
Hershey, PA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Englewood, CO
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Woodbury, MN
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Rock Hill, NC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Rock Hill, NC
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Tacoma, WA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Marietta, GA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated:  2/13/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated: 2/13/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma
Status: Enrolling
Updated:  4/17/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma
Status: Enrolling
Updated: 4/17/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  4/18/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 4/18/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
BARC: A Secreted Marker of Kidney Cancer
Status: Enrolling
Updated:  7/31/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
BARC: A Secreted Marker of Kidney Cancer
Status: Enrolling
Updated: 7/31/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
New York Medical College
mi
from
Valhalla, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Columbia University Medical Center
mi
from
New York, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Oregon Health and Science University
mi
from
Portland, OR
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Medical University of South Carolina
mi
from
Charleston, SC
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials